Vaxart Past Earnings Performance

Past criteria checks 0/6

Vaxart's earnings have been declining at an average annual rate of -30.1%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 6.8% per year.

Key information

-30.1%

Earnings growth rate

13.3%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-6.8%
Return on equity-94.6%
Net Margin-543.2%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Vaxart makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:NB11 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2414-76230
31 Mar 249-82230
31 Dec 237-82230
30 Sep 234-89240
30 Jun 232-101260
31 Mar 231-108290
31 Dec 220-108290
30 Sep 220-105290
30 Jun 220-93270
31 Mar 220-80230
31 Dec 211-70220
30 Sep 211-64210
30 Jun 211-54200
31 Mar 212-47190
31 Dec 204-32150
30 Sep 208-25110
30 Jun 208-2290
31 Mar 207-1960
31 Dec 1910-1960
30 Sep 198-1760
30 Jun 198-1860
31 Mar 198-2270
31 Dec 184-1870
30 Sep 183-1560
30 Jun 184-1250
31 Mar 185-730
31 Dec 176-1230
30 Sep 179-1630
31 Dec 168-1930
31 Dec 150-2230

Quality Earnings: NB11 is currently unprofitable.

Growing Profit Margin: NB11 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: NB11 is unprofitable, and losses have increased over the past 5 years at a rate of 30.1% per year.

Accelerating Growth: Unable to compare NB11's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NB11 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: NB11 has a negative Return on Equity (-94.56%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies